| scholarly article | Q13442814 |
| P2093 | author name string | Olivier Elemento | |
| Tarun M Kapoor | |||
| Corynn Kasap | |||
| P2860 | cites work | RNA-guided human genome engineering via Cas9 | Q24598394 |
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| A "slow" homotetrameric kinesin-related motor protein purified from Drosophila embryos | Q24634178 | ||
| Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism | Q27685265 | ||
| Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen | Q28146108 | ||
| Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients | Q28303521 | ||
| Next-generation DNA sequencing | Q29547447 | ||
| The cancer genome | Q29547643 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Kinesin-12 differentially affects spindle assembly depending on its microtubule substrate | Q30541847 | ||
| EGF-induced centrosome separation promotes mitotic progression and cell survival | Q30573126 | ||
| Recognizing and exploiting differences between RNAi and small-molecule inhibitors | Q34074675 | ||
| Identification and validation of protein targets of bioactive small molecules | Q34121221 | ||
| A rapid and general assay for monitoring endogenous gene modification | Q34129397 | ||
| Kinesins and cancer. | Q34289839 | ||
| Antitumor activity of a kinesin inhibitor | Q34318656 | ||
| A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility | Q34581520 | ||
| Target identification and mechanism of action in chemical biology and drug discovery | Q34626974 | ||
| The development of proteasome inhibitors as anticancer drugs | Q35773857 | ||
| Mitotic kinesins: prospects for antimitotic drug discovery. | Q36107322 | ||
| Mutagenesis and homologous recombination in Drosophila cell lines using CRISPR/Cas9. | Q39044698 | ||
| The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response | Q39360397 | ||
| Using transcriptome sequencing to identify mechanisms of drug action and resistance | Q39397734 | ||
| Cancer drug's survivin suppression called into question | Q84311783 | ||
| P433 | issue | 8 | |
| P921 | main subject | CRISPR | Q412563 |
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 626-628 | |
| P577 | publication date | 2014-06-15 | |
| P1433 | published in | Nature Chemical Biology | Q904026 |
| P1476 | title | DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets | |
| P478 | volume | 10 |
| Q26852489 | Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference |
| Q38768845 | Advances in identification and validation of protein targets of natural products without chemical modification |
| Q87317607 | Application guide for omics approaches to cell signaling |
| Q38708498 | Applications of CRISPR genome editing technology in drug target identification and validation |
| Q48376848 | CRISPR Approaches to Small Molecule Target Identification |
| Q56362775 | CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool |
| Q102063582 | CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries |
| Q38516454 | CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies |
| Q42577802 | CRISPR-Cas9-based target validation for p53-reactivating model compounds. |
| Q93139098 | CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML |
| Q64081762 | CRISPR/Cas9 - An evolving biological tool kit for cancer biology and oncology |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q97643334 | Chemical strategies to overcome resistance against targeted anticancer therapeutics |
| Q90080192 | Chemoresistance in Pancreatic Cancer |
| Q33906319 | Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology |
| Q38775271 | Common pitfalls in preclinical cancer target validation |
| Q39051110 | Cornerstones of CRISPR-Cas in drug discovery and therapy |
| Q34045952 | Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma |
| Q96610114 | Discovering and validating cancer genetic dependencies: approaches and pitfalls |
| Q26782747 | Enabling functional genomics with genome engineering |
| Q38635314 | Functional genomics to uncover drug mechanism of action. |
| Q38732535 | Genome-wide genetic screening with chemically mutagenized haploid embryonic stem cells |
| Q36482298 | High-Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells |
| Q38498286 | High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges |
| Q40201379 | Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies |
| Q60301717 | Involvement of C-terminal truncation mutation of kinesin-5 in resistance to kinesin-5 inhibitor |
| Q53690747 | KIF15 nanomechanics and kinesin inhibitors, with implications for cancer chemotherapeutics |
| Q30826773 | Kinesin-5 inhibitor resistance is driven by kinesin-12 |
| Q50076078 | Leveraging Chemotype-Specific Resistance for Drug Target Identification and Chemical Biology |
| Q36273198 | Melanoma genome evolution across species |
| Q62496001 | Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery |
| Q38384489 | Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment |
| Q39171961 | Non-kinase targets of protein kinase inhibitors |
| Q38904862 | Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. |
| Q39031286 | Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets |
| Q54976863 | Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q46554724 | Synthetic Gene Expression Circuits for Designing Precision Tools in Oncology |
| Q26775582 | Synthetic biology for pharmaceutical drug discovery |
| Q48103480 | Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes |
| Q49218909 | YM155 inhibits topoisomerase function |
| Q36210899 | YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice |
| Q100407541 | enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9 |
Search more.